Abbott blood screening
This article was originally published in The Gray Sheet
Executive Summary
Abbott announces biologics license approval Jan. 18 for a fully automated blood screening test for antibodies to human T-lymphotropic virus Types I and II on the firm's Prism system. The HTLV-I and II retroviruses are associated with leukemia and neurological disorders, among other diseases, and are screened for in all U.S. blood donations. Abbott says the new test offers an alternative to its HTLV-I/II assay approved in 1997 that runs on the semi-automated Commander system. Prism, which launched in the U.S. in 2005, also runs four tests for hepatitis
You may also be interested in...
EU Health Ministers To Deliberate Over Commission’s Pharma Strategy
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.
Latest Vascepa Lawsuit Plunges Hikma Into Induced Infringement Battle
Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.
EU Approval Of COVID-19 Vaccines Possible In Weeks
The European Medicines Agency will continue working over the Christmas period so that it can complete its assessment of the newly filed marketing applications for BioNTech/Pfizer’s and Moderna’s COVID-19 vaccines as soon possible.
Need a specific report? 1000+ reports available
Buy Reports